This is a fully-fledged industry-not just growers selling flowers. There are lighting suppliers, construction crews, farmers, soil and fertilizer developers, and serious R&D.
In a significant development, the DEA is considering rescheduling cannabis from a Schedule I to a Schedule III drug, potentially reshaping the regulatory landscape and impacting research.
The U.S. cannabis industry has grown significantly, projected to surpass $50 billion in sales, yet faces numerous challenges due to regulatory, banking, and competitive pressures.
The cannabis industry depends on trust, transparency, and ethical business practices to function properly. When a company provides months of professional services and is not compensated as agreed, it raises serious concerns about financial accountability within the market.